{
    "DATE": " 9-APR-1987 12:16:15.79",
    "TOPICS": [
        "earn"
    ],
    "PLACES": [
        "usa"
    ],
    "NEWID": "15703",
    "TEXT": {
        "TITLE": "MONSANTO <MTC> UNIT SEES OPERATING LOSS IN 1987",
        "DATELINE": "    NEW YORK, April 9 - ",
        "BODY": "Monsanto Corp's G.D. Searle and Co unit\nsaid it will report an operating loss for 1987, mainly due to\nexpenses for research and development.\n    Searle chairman Sheldon Gilgore said Searle's operating\nloss in 1987 will be less than the 87 mln dlr operating loss in\n1986.\n    He said Searle's first quarter sales will be up 21.8 pct to\n179 mln dlrs from 147 mln dlrs in the year ago quarter. In 1986\nSearle's sales were 665 mln dlrs.\n    Gilgore said the company intends to have sales of three\nbillion dlrs by the mid-1990s.\n    He said the company anticipates approval in Japan, the\nU.S., Italy, Spain and the U.K. for its ulcer treatment drug\nCytotech.\n    He also said that in a paper not yet published the drug was\nshown to prevent a flare-up of ulcers for a longer period of\ntime than Tagamet, made by SmithKline Beckman Corp <SKB>.\n    Other drugs in Searle's pipeline include tissue plasminogen\nactivator (TPA), made by a different process than Genentech's\n<GENE> TPA, expected to be approved for marketing this year.\n   \n Reuter\n\u0003"
    },
    "ORGS": [
        "imf"
    ],
    "PEOPLE": [
        "balladur"
    ],
    "EXCHENGES": [
        "nyce"
    ]
}